NEWS | BEAM Alliance

NEWS

Combioxin Announces an Oral Presentation on CAL02 clinical results at ESICM 2018

Combioxin Announces an Oral Presentation on CAL02 clinical results at ESICM 2018

Geneva, Switzerland, 18 October 2018 – Combioxin SA, a clinical-stage biotechnology company focused on the development of innovative treatments for severe and resistant infections, announced today that first-in-human clinical results with CAL02 in severe pneumonia patients in ICU will be presented during the ESICM’s annual congress, LIVES 2018, taking place October 20-24, 2018 in Paris, France.

Full PR available here